3
Clinical Trials associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center) / SuspendedEarly Phase 1IIT Personalized neoantigen peptide vaccine based on polylactic acid microspheres for cancer treatment
Start Date30 Jan 2024 |
Sponsor / Collaborator- |
PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, PD1/PD-L1 Inhibitor-Refractory Melanoma, and Pretreated Non-Small Cell Lung Cancer
This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or does not respond to treatment (refractory) or stage III-IV non-small cell lung cancer. Personalized neo-antigen peptide vaccine is a product that combines multiple patient specific neo-antigens. Given personalized neo-antigen peptide vaccine together with Th1 polarizing adjuvant poly ICLC may induce a polyclonal, poly-epitope, cytolytic T cell immunity against the patient's tumor.
/ SuspendedEarly Phase 1IIT Exploration of new technology of personalized neoantigen peptide vaccine in the adjuvant treatment of refractory colorectal cancer patients with recurrence and metastasis
100 Clinical Results associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)
100 Translational Medicine associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)
100 Patents (Medical) associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)
100 Deals associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)